ZBIO News and Press, ProShares UltraPro Short NASDAQ Biotechnology From 11/21/25

2025-11-21 11:03:32 ET More on healthcare TG Therapeutics: Concerns About Slowing Growth And New Competition TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing Eli Lilly: This Breakout Rally Has More Room To Run Lilly market cap excee...

2025-11-12 09:55:32 ET More on Zenas BioPharma, Inc. Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal Zenas BioPharma rises after Wedbush raises price target Zenas climbs on licensing deal with InnoCare Seeking Alpha’s Quant Rating on ...

- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

2025-10-28 10:15:19 ET H.C. Wainwright analyst issues BUY recommendation for ZBIO on October 28, 2025 10:08AM ET. The previous analyst recommendation was Buy. ZBIO was trading at $30.1491 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2025-10-27 13:12:03 ET DENVER, Colo., Oct 27, 2025 ( 247marketnews.com )- Wall Street’s midday tempo is upbeat as a medley of corporate headlines drive trading momentum across entertainment, biotech, and technology sectors. VENU (NYSE:VENU) continues to strike all the rig...

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Compan...

2025-10-21 16:52:08 ET More on Zenas BioPharma, Inc. Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS Read the full article on Seeking Alpha For further details see: Zenas...

2025-10-09 14:20:24 ET More on Zenas BioPharma, Inc. Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS Zenas climbs on licensing deal with InnoCare Zenas BioPharma and Royalty ...

2025-10-09 08:00:57 ET Thesis Read the full article on Seeking Alpha For further details see: Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal